ArticleJournal for immunotherapy of cancer2019

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.

Kohei Shitara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.